Aptuit’s Clinical Trial Business Acquired by Catalent

On August 22, 2011, Catalent Pharma Solutions, Inc., and Aptuit, LLC, announced an agreement for Catalent to acquire the Clinical Trial Supplies business of Aptuit for cash consideration of $410 million on a cash and debt-free basis. Cravath represented Aptuit in connection with this transaction. The completion of the transaction is subject to customary closing conditions and is expected to occur by the end of the calendar year.

The Cravath team included partners Thomas E. Dunn and Craig F. Arcella on corporate matters; and partner Andrew W. Needham on tax matters.